Drug Trial Radar · NCT07847905
A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Oct 19, 2030
Study completion Aug 19, 2031
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors. For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor Cancer
Interventions
LM-364 for injectionDrug
Q3W, Intravenous infusion
TislelizumabDrug
Q3W, Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: 78 Weeks
- Adverse events (AEs)Time frame: 78 weeks
- serious adverse events (SAEs)Time frame: 78 weeks
- TemperaturesTime frame: 78 weeks
- Pulse in BPMTime frame: 78 weeks
- Blood Pressure in mmHgTime frame: 78 weeks
- Weight in KgTime frame: 78 weeks
- Height in centimeterTime frame: 78 weeks
- Laboratory examinations--Blood Routine examination-Complete Blood CountTime frame: 78 weeks
- Laboratory examinations--Blood biochemistry- Electrolytes and Metabolic ParametersTime frame: 78 weeks
- Laboratory examinations-Urine Routine test-UrinalysisTime frame: 78 weeks
- Laboratory examinations--Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)Time frame: 78 weeks
- Laboratory examinations--Thyroid function-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)Time frame: 78 weeks
- Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in PRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
- ECOG score-Cooperative Oncology Group scoreTime frame: 78 weeks
- Objective Response Rate (ORR)Time frame: 52 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
the first affiliated hospital of Henan medical University
Xinxiang, Henan, China
Taihe Hospital Affiliated Hospital of Hubei University of Medicine
Shiyan, Hubei, China
Hunan cancer hospital
Changsha, Hunan, China
Liaocheng People's Hospital
Liaocheng, Shandong, China
FuDan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
The First School of Medicine, School of Information and Engineering,The First Affliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.